Literature DB >> 9108610

Viral hepatitis in the Bhutanese population: preliminary results of a seroepidemiological investigation.

G Da Villa1, A Andjaparidze, M Cauletti, E Franco, M Roggendorf, A Sepe, L Zaratti.   

Abstract

A seroepidemiological study of the prevalence of markers related to the most common forms of viral hepatitis was carried out in Bhutan on 1,666 healthy people of both sexes, from the general population. A group of 440 pregnant women were screened separately. Our results suggest that in Bhutan, hepatitis A and hepatitis B are widespread, while there is a low prevalence of hepatitis C and E. Anti-HAV (anti-hepatitis A virus) was found in all 171 tested subjects over 12 years of age, and anti-HBc (anti-hepatitis B core antigen) in 63.1% of 1,666 tested people. On the other hand, anti-HEV proved positive in 2.0% of 257 tested subjects, and anti-HCV in only 1.3% of 611 tested subjects. Hepatitis B surface antigen (HBsAg) was found in 5.9% of the sample from the general population (5.2% in children, 5.6% in young people and 6.3% in adults) and in 5.4% of the pregnant women. Furthermore, 29.1% of HBsAg-positive pregnant women were HBeAg- and HBV DNA-positive, too. Comparing the pregnant women's prevalence data to those found in children, we suggest that the main route of HBV transmission in the Bhutanese population is vertical, from mother to child; this finding is important for the implementation of a correct anti-HBV vaccination strategy in Bhutan.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9108610     DOI: 10.1016/s0923-2516(97)89894-9

Source DB:  PubMed          Journal:  Res Virol        ISSN: 0923-2516


  2 in total

Review 1.  Status and progress of hepatitis B control through vaccination in the South-East Asia Region, 1992-2015.

Authors:  Lana Childs; Sigrun Roesel; Rania A Tohme
Journal:  Vaccine       Date:  2017-11-22       Impact factor: 3.641

2.  Prevalence of HBV and HCV infections, Bhutan, 2017: Progress and next steps.

Authors:  N Tshering; G P Dhakal; U Wangchuk; S Wangdi; L Khandu; S Pelden; F Nogareda; M K Patel; Y J F Hutin; K Wannemuehler; B B Rewari; S Wangchuk
Journal:  BMC Infect Dis       Date:  2020-07-08       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.